Chemotherapy-induced organ toxicity mitigation Open access Peer reviewed

Olmesartan-Loaded PLGA Nanoparticles Attenuate Methotrexate-Induced Kidney Injury: Association with the AT1R/ERK1/2 Signaling Axis

Omar M. Alawad, Norhan Tantawy, Soha Elsalhy, Asmaa A. Ahmed and 2 more

Pharmaceuticals | Sep 15, 2026

Scollr summary

What this paper is about

PLGA-based nanoencapsulation enhanced the nephroprotective efficacy of OLM against MTX-induced nephrotoxicity and was associated with the modulation of the AT1R/ERK1/2 signaling axis.

Full abstract

Read the full abstract

Background/Objectives: Methotrexate (MTX) is an effective antineoplastic and immunosuppressive agent whose clinical use can be limited by nephrotoxicity. Increasing evidence suggests that dysregulated angiotensin II-mediated signaling contributes to MTX-induced renal injury. Olmesartan (OLM), an angiotensin II type 1 receptor (AT1R) blocker, possesses renoprotective properties; however, its therapeutic efficacy may be limited by suboptimal pharmacokinetics and tissue deli\very. This study aimed to develop OLM-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles (OLM-PLGA) and investigate their nephroprotective efficacy and underlying molecular mechanisms in MTX-induced nephrotoxicity. Methods: OLM-PLGA nanoparticles were prepared and evaluated for their physicochemical characteristics. The in vivo nephroprotective effects of OLM-PLGA were investigated in male Sprague–Dawley rats, which were allocated into four groups: OLM (10 mg/kg), OLM-PLGA (10 mg/kg), MTX-treated, and normal control. Renal function, oxidative stress, inflammation, apoptosis, and fibrosis were assessed, together with renal gene expression of AT1R and extracellular signal-regulated kinase 1/2 (ERK1/2). Results: Compared with free OLM, OLM-PLGA provided superior protection against MTX-induced renal dysfunction and oxidative stress, as evidenced by improved renal function and enhanced antioxidant defense. OLM-PLGA also exerted greater anti-inflammatory and anti-apoptotic effects and attenuated renal fibrotic changes, accompanied by reduced renal expression of α-smooth muscle actin and collagen. These protective effects were associated with decreased AT1R gene expression and suppression of downstream ERK1/2 signaling. Conclusions: PLGA-based nanoencapsulation enhanced the nephroprotective efficacy of OLM against MTX-induced nephrotoxicity and was associated with the modulation of the AT1R/ERK1/2 signaling axis. OLM-PLGA may therefore represent a promising nanotherapeutic approach for improving OLM delivery and renal protection during MTX treatment.

Direct answer

What can I do from this paper page?

Use this page to scan "Olmesartan-Loaded PLGA Nanoparticles Attenuate Methotrexate-Induced Kidney Injury: Association with the AT1R/ERK1/2 Signaling Axis" quickly: start with the summary and abstract, then check the authors, source, topics, and related papers. From here, open Scollr to follow Chemotherapy-induced organ toxicity mitigation research, save the paper, or map adjacent work.

Authors

Researchers on this paper

Omar M. Alawad

first | Islamic University of Madinah

Norhan Tantawy

middle | Helwan University

Soha Elsalhy

middle | Misr University for Science and Technology

Asmaa A. Ahmed

middle | Helwan University

Shahira Nofal

middle | Helwan University | ORCID 0000-0003-0405-9002

Eman M. Raafat

last | Helwan University

Research areas

Follow related topics

Citation

BibTeX

@article{Alawad2026Olmesartan,
  title = {Olmesartan-Loaded PLGA Nanoparticles Attenuate Methotrexate-Induced Kidney Injury: Association with the AT1R/ERK1/2 Signaling Axis},
  author = {Omar M. Alawad and Norhan Tantawy and Soha Elsalhy and Asmaa A. Ahmed and Shahira Nofal and Eman M. Raafat},
  journal = {Pharmaceuticals},
  year = {2026},
  doi = {10.3390/ph19091462},
  url = {https://doi.org/10.3390/ph19091462}
}

FAQ

Using this paper in a discovery workflow

How do I find related work for this paper?

Use the related papers and topic links on this page as starting points. In Scollr, you can also open the paper and build a literature map around its references, citing papers, and related work.

How can I keep up with new Chemotherapy-induced organ toxicity mitigation research papers?

Follow Chemotherapy-induced organ toxicity mitigation research in Scollr. New papers from the topic flow into a personalized feed, and you can save useful studies to revisit later.

Can I cite this paper from this page?

This page includes a static BibTeX block for Olmesartan-Loaded PLGA Nanoparticles Attenuate Methotrexate-Induced Kidney Injury: Association with the AT1R/ERK1/2 Signaling Axis. Always verify the DOI, source, and publication details against the publisher record before submitting a manuscript.

Follow this research in Scollr

Follow the topics and authors behind this paper, save useful studies, and build a literature map when you are ready to go deeper.

Get the app